Summary
Signal counts
Assets tracked: 2
Watchlist assets: 2
Registry stop assets: 1
Sponsor overview
University of Colorado, Denver
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT05887609 | https://clinicaltrials.gov/study/NCT04535102 | https://clinicaltrials.gov/study/NCT04659044
Assets
Linked programs
- Mirvetuximab Soravtansine-gynx: Watchlist Signal (2/5)
- Polatuzumab Vedotin: Registry Stop Signal (4/5)